Unlocking the Drug Delivery Opportunity for Genomic Medicine
Our ATLAS LNP Platform
Building on a strong intellectual property portfolio licensed from Tufts University, Hopewell has established and leveraged its novel ATLAS platform to develop an extensive and rapidly growing library of ionizable lipids and LNP leads.
The deep experience of Hopewell's scientific team has driven a very high success rate in identifying novel active lipid structures that enable the design of LNPs for targeted, efficient, and safe delivery of diverse cargoes to specific organs, tissues, and cells throughout the body via systemic and local administration.
As of the end of 2022, the ATLAS platform has been successfully employed to generate and verify a library of over 700 ionizable lipids and over 80 LNP leads targeting a wide range of organs with diverse mRNA cargoes:
Organs: Liver, Lung, Lymph Nodes, Spleen, Brain, Kidney, Eye, Ear
Cargoes: mRNA, siRNA, DNA, gene editing apparatus, small molecules, mixed cargoes
Key Scientific Publications
Hopewell was established with scientific data featured in over a decade of leading publications that highlight the novelty of the company's LNP technology and its potential to address the unmet needs of patients.